| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Citrazinic acid targets 3-dehydroquinate dehydratase, an enzyme in the shikimate pathway of Mycobacterium tuberculosis, inhibiting its activity. This pathway is essential for the biosynthesis of aromatic amino acids in bacteria and is absent in mammals, making it a potential target for antibacterial drug development. The compound's fluorescence properties are dependent on its aggregation state and chemical environment.
|
|---|---|
| ln Vitro |
Citrazinic acid inhibits 3-dehydroquinate dehydratase from Mycobacterium tuberculosis. It is a weakly fluorescent compound, and its optical properties change with aggregation state and pH. The compound strongly tends to form dimers at high concentrations. Preliminary studies suggest that citrazinic acid may exhibit antimicrobial properties.
|
| ln Vivo |
In vivo activity data for citrazinic acid are limited, as it is primarily a research compound and biochemical tool. Its antibacterial activity against Mycobacterium tuberculosis has been demonstrated in vitro, but in vivo efficacy has not been extensively studied. The compound's fluorescence properties may be useful for imaging applications.
|
| Enzyme Assay |
In vitro assays for citrazinic acid involve measuring the inhibition of 3-dehydroquinate dehydratase activity. The enzyme is incubated with its substrate, 3-dehydroquinate, in the presence of varying concentrations of citrazinic acid. The formation of the product, 3-dehydroshikimate, is measured spectrophotometrically at 234 nm. IC50 values are calculated from inhibition curves.
|
| Cell Assay |
Cellular assays for citrazinic acid are performed using Mycobacterium tuberculosis cultures. Bacteria are cultured in appropriate media and treated with citrazinic acid at varying concentrations. Bacterial growth is assessed by measuring optical density or colony-forming units (CFU). The compound's minimum inhibitory concentration (MIC) is determined. Cytotoxicity may be assessed in mammalian cell lines.
|
| Animal Protocol |
In vivo animal studies with citrazinic acid are limited, as it is primarily a research compound. If used, it would likely be administered in a mouse model of tuberculosis infection. Efficacy would be assessed by measuring bacterial burden in the lungs and spleen. Dosing regimens would be determined based on preliminary pharmacokinetic data.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for citrazinic acid are limited【L7】. Its molecular weight is 155.11 g/mol. The compound is a polar, water-soluble molecule, which may limit its ability to cross biological membranes. For research use, it is typically dissolved in DMSO or water.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for citrazinic acid are limited【L7】. As a weakly fluorescent compound, it is not expected to be highly toxic. However, no systematic toxicity studies have been reported. The compound should be handled with standard laboratory safety precautions【L7】.
|
| References | |
| Additional Infomation |
Citrazine acid is an aromatic carboxylic acid that belongs to the pyridine class of compounds.
Citrazinic acid is a research compound used as a biochemical tool and a fluorescent probe. Its ability to inhibit 3-dehydroquinate dehydratase from Mycobacterium tuberculosis makes it a potential lead compound for the development of new anti-tuberculosis agents【L7】. The compound is also used in the synthesis of pyrimidinone and oxazinone derivatives. It is not approved for clinical use and is intended for laboratory research only【L7】. |
| Molecular Formula |
C6H5NO4
|
|---|---|
| Molecular Weight |
155.11
|
| Exact Mass |
155.021
|
| CAS # |
99-11-6
|
| PubChem CID |
7425
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
630.3±55.0 °C at 760 mmHg
|
| Melting Point |
>300 °C(lit.)
|
| Flash Point |
335.0±31.5 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.686
|
| LogP |
-1.5
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
276
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CSGQJHQYWJLPKY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H5NO4/c8-4-1-3(6(10)11)2-5(9)7-4/h1-2H,(H,10,11)(H2,7,8,9)
|
| Chemical Name |
2-hydroxy-6-oxo-1H-pyridine-4-carboxylic acid
|
| Synonyms |
2,6-Dihydroxyisonicotinate Kyselina citrazinova Citrazinic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4470 mL | 32.2352 mL | 64.4704 mL | |
| 5 mM | 1.2894 mL | 6.4470 mL | 12.8941 mL | |
| 10 mM | 0.6447 mL | 3.2235 mL | 6.4470 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
